Literature DB >> 23222532

Treatment patterns for prostate cancer: comparison of Medicare claims data to medical record review.

Steven T Fleming1, Ann S Hamilton, Susan A Sabatino, Gretchen G Kimmick, Xiao-Cheng Wu, Jean B Owen, Bin Huang, Wenke Hwang.   

Abstract

BACKGROUND: As evidence-based guidelines increasingly define standards of care, the accurate reporting of patterns of treatment becomes critical to determine if appropriate care has been provided. We explore the level of agreement between claims and record abstraction for treatment regimens for prostate cancer.
METHODS: Medicare claims data were linked to medical records abstraction using data from the Centers for Disease Control and Prevention's National Program of Cancer Registry-funded Breast and Prostate Patterns of Care study. The first course of therapy included surgery, radiation therapy (RT), and hormonal therapy with luteinizing hormone-releasing hormone agonists.
RESULTS: The linked sample included 2765 men most (84.7%) of whom had stage II prostate cancer. Agreement was excellent for surgery (κ=0.92) and RT (κ=0.92) and lower for hormonal therapy (κ=0.71); however, most of the discrepancies were due to greater number of patients reported who received hormonal therapy in the claims database than in the medical records database. For some standard multicomponent management strategies sensitivities were high, for example, hormonal therapy with either combination RT (86.9%) or cryosurgery (96.6%).
CONCLUSIONS: Medicare claims are sensitive for determining patterns of multicomponent care for prostate cancer and for detecting use of hormonal therapy when not reported in the medical records abstracts.

Entities:  

Mesh:

Year:  2014        PMID: 23222532      PMCID: PMC5874805          DOI: 10.1097/MLR.0b013e318277eba5

Source DB:  PubMed          Journal:  Med Care        ISSN: 0025-7079            Impact factor:   2.983


  25 in total

1.  Underreporting of computed tomography and magnetic resonance imaging procedures in inpatient claims data.

Authors:  Clara E Dismuke
Journal:  Med Care       Date:  2005-07       Impact factor: 2.983

2.  Challenges of using medical insurance claims data for utilization analysis.

Authors:  Patrick T Tyree; Bonnie K Lind; William E Lafferty
Journal:  Am J Med Qual       Date:  2006 Jul-Aug       Impact factor: 1.852

3.  External validation of medicare claims for breast cancer chemotherapy compared with medical chart reviews.

Authors:  Xianglin L Du; Charles R Key; Lois Dickie; Ronald Darling; Jane M Geraci; Dong Zhang
Journal:  Med Care       Date:  2006-02       Impact factor: 2.983

4.  The utility of administrative data for measuring adherence to cancer surveillance care guidelines.

Authors:  Gregory S Cooper; Lonni Schultz; Janine Simpkins; Jennifer Elston Lafata
Journal:  Med Care       Date:  2007-01       Impact factor: 2.983

5.  Accuracy and completeness of Medicare claims data for surgical treatment of breast cancer.

Authors:  X Du; J L Freeman; J L Warren; A B Nattinger; D Zhang; J S Goodwin
Journal:  Med Care       Date:  2000-07       Impact factor: 2.983

6.  Information on radiation treatment in patients with breast cancer: the advantages of the linked medicare and SEER data. Surveillance, Epidemiology and End Results.

Authors:  X Du; J L Freeman; J S Goodwin
Journal:  J Clin Epidemiol       Date:  1999-05       Impact factor: 6.437

7.  Validity of cancer registry data for measuring the quality of breast cancer care.

Authors:  Jennifer L Malin; Katherine L Kahn; John Adams; Lorna Kwan; Marianne Laouri; Patricia A Ganz
Journal:  J Natl Cancer Inst       Date:  2002-06-05       Impact factor: 13.506

8.  Utility of the SEER-Medicare data to identify chemotherapy use.

Authors:  Joan L Warren; Linda C Harlan; Angela Fahey; Beth A Virnig; Jean L Freeman; Carrie N Klabunde; Gregory S Cooper; Kevin B Knopf
Journal:  Med Care       Date:  2002-08       Impact factor: 2.983

Review 9.  Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer.

Authors:  Timothy J Wilt; Roderick MacDonald; Indulis Rutks; Tatyana A Shamliyan; Brent C Taylor; Robert L Kane
Journal:  Ann Intern Med       Date:  2008-02-04       Impact factor: 25.391

10.  Gonadotropin-releasing hormone agonist use in men without a cancer registry diagnosis of prostate cancer.

Authors:  Yong-fang Kuo; James S Goodwin; Vahakn B Shahinian
Journal:  BMC Health Serv Res       Date:  2008-07-14       Impact factor: 2.655

View more
  5 in total

1.  Clinical and Demographic Factors Associated With Receipt of Non Guideline-concordant Initial Therapy for Nonmetastatic Prostate Cancer.

Authors:  Ann S Hamilton; Steven T Fleming; Dian Wang; Michael Goodman; Xiao-Cheng Wu; Jean B Owen; Mary Lo; Alex Ho; Roger T Anderson; Trevor Thompson
Journal:  Am J Clin Oncol       Date:  2016-02       Impact factor: 2.339

2.  Enhancing cancer registry data for comparative effectiveness research (CER) project: overview and methodology.

Authors:  Vivien W Chen; Christie R Eheman; Christopher J Johnson; Monique N Hernandez; David Rousseau; Timothy S Styles; Dee W West; Meichin Hsieh; Anne M Hakenewerth; Maria O Celaya; Randi K Rycroft; Jennifer M Wike; Melissa Pearson; Judy Brockhouse; Linda G Mulvihill; Kevin B Zhang
Journal:  J Registry Manag       Date:  2014

3.  Radical Prostatectomy or External Beam Radiation Therapy vs No Local Therapy for Survival Benefit in Metastatic Prostate Cancer: A SEER-Medicare Analysis.

Authors:  Raj Satkunasivam; Andre E Kim; Mihir Desai; Mike M Nguyen; David I Quinn; Leslie Ballas; Juan Pablo Lewinger; Mariana C Stern; Ann S Hamilton; Monish Aron; Inderbir S Gill
Journal:  J Urol       Date:  2015-02-21       Impact factor: 7.450

4.  Researching the Appropriateness of Care in the Complementary and Integrative Health Professions Part 5: Using Patient Records: Selection, Protection, and Abstraction.

Authors:  Carol P Roth; Ian D Coulter; Lisa S Kraus; Gery W Ryan; Gary Jacob; Joyce S Marks; Eric L Hurwitz; Howard Vernon; Paul G Shekelle; Patricia M Herman
Journal:  J Manipulative Physiol Ther       Date:  2019-06-27       Impact factor: 1.437

5.  Using health insurance claims data to assess long-term disease progression in a prostate cancer cohort.

Authors:  Saira Khan; Sanah Vohra; Laura Farnan; Shekinah N C Elmore; Khadijah Toumbou; Madhav K C; Elizabeth T H Fontham; Edward S Peters; James L Mohler; Jeannette T Bensen
Journal:  Prostate       Date:  2022-07-26       Impact factor: 4.012

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.